Inventor · disambiguated record
Robert Graziano
Also filed as: GRAZIANO ROBERT · GRAZIANO ROBERT F
24 granted patents·15 pending applications·2,093 citations·filing 1993–2022
97Inventor score
Files withBRISTOL MYERS SQUIBB CO11MEDAREX INC11UNIV MASSACHUSETTS5AMBROSINO DONNA M3GRAZIANO ROBERT2
Top patents by PatentIndex Score
39 records- 0199US5922845ATherapeutic multispecific compounds comprised of anti-Fcα receptor antibodiesMEDAREX INC·Filed 1996·Granted Jul 13, 1999·448 cites·24 claims
- 0298US5837243ATherapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1996·Granted Nov 17, 1998·545 cites·18 claims
- 0397US6270765B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1998·Granted Aug 7, 2001·215 cites·9 claims
- 0496US7625559B2Antibodies against Clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2005·Granted Dec 1, 2009·47 cites·4 claims
- 0596US7452535B2Methods of treatment using CTLA-4 antibodiesMEDAREX INC·Filed 2003·Granted Nov 18, 2008·70 cites·18 claims
- 0696US6303755B1Therapeutic multispecific compounds comprised of anti-FCA receptor antibodiesMEDAREX INC·Filed 1999·Granted Oct 16, 2001·116 cites·17 claims
- 0795US7387776B2Human monoclonal antibodies against CD30MEDAREX INC·Filed 2003·Granted Jun 17, 2008·70 cites·15 claims
- 0894US8257709B2Antibodies against Clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2009·Granted Sep 4, 2012·22 cites·23 claims
- 0993US9789182B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 17, 2017·11 cites·15 claims
- 1093US8142778B2Methods of treatment using CTLA-4 antibodiesDAVIS THOMAS ANDREW·Filed 2008·Granted Mar 27, 2012·25 cites·75 claims
- 1193US6410690B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDAREX INC·Filed 1995·Granted Jun 25, 2002·91 cites·17 claims
- 1293US6395272B1Therapeutic compounds comprised of anti-Fc receptor antibodiesMEDEREX INC·Filed 1998·Granted May 28, 2002·127 cites·6 claims
- 1393US6365161B1Therapeutic compounds comprised of anti-FC receptor binding agentsMEDAREX INC·Filed 1999·Granted Apr 2, 2002·113 cites·20 claims
- 1492US8236311B2Antibodies against clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2009·Granted Aug 7, 2012·15 cites·25 claims
- 1592US6682928B2Cells expressing anti-Fc receptor binding componentsMEDAREX INC·Filed 1998·Granted Jan 27, 2004·89 cites·24 claims
- 1689US7378504B2Human monoclonal antibodies to Fc gamma receptor I (CD64)MEDAREX INC·Filed 2005·Granted May 27, 2008·19 cites·8 claims
- 1784US10688180B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jun 23, 2020·2 cites·15 claims
- 1884US6193966B1Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodiesMEDERAX INC·Filed 1997·Granted Feb 27, 2001·48 cites·29 claims
- 1983US11242393B2Antibodies against MICA and/or MICB and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 8, 2022·3 cites·19 claims
- 2083US8609111B2Antibodies against clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2012·Granted Dec 17, 2013·4 cites·30 claims
- 2181US8088377B2Human monoclonal antibodies against CD30KELER TIBOR·Filed 2008·Granted Jan 3, 2012·4 cites·10 claims
- 2280US9217029B2Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2013·Granted Dec 22, 2015·2 cites·25 claims
- 2375US2021269511A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2020·Application pending·0 cites
- 2466US2022127363A1Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccineBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2566US2018208643A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2018·Application pending·0 cites
- 2663US7316812B2Cells expressing anti-Fc receptor binding componentsCELLDEX THERAPEUTICS INC·Filed 2004·Granted Jan 8, 2008·0 cites·25 claims
- 2763US2022281980A1Antibodies against mica and/or micb and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2859US2016152694A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2015·Application pending·0 cites
- 2957US2008187547A1Irta-5 antibodies and their usesGRAZIANO ROBERT·Filed 2007·Application pending·0 cites
- 3054US2001014328A1Therapeutic multispecific compounds comprised of anti-Fcalpha receptor antibodiesMEDERAX INC·Filed 2001·Application pending·0 cites
- 3152US2019382490A1Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccineBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 3251US2015290316A1Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 3350US2005266008A1Human anti-IRTA-5 antibodiesMEDAREX INC·Filed 2005·Application pending·0 cites
- 3450US2016264670A1Immunotherapeutic dosing regimens and combinations thereofBRISTOL MYERS SQUIBB CO·Filed 2014·Application pending·0 cites
- 3549US2023087600A1Il-10 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 3649US2018099045A1Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3744US2008247944A1Irta-2 Antibodies and Their UsesGRAZIANO ROBERT·Filed 2006·Application pending·0 cites
- 3837US2017355768A1Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)BRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 3928US5313214AScaled multiple function nonlinear FM waveformGRUMMAN AEROSPACE CORP·Filed 1993·Granted May 17, 1994·7 cites·18 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →